

Amendments to the Claims:

Non-elected Claims 1-12 are canceled without prejudice or disclaimer; Claim 13 is amended; and new Claims 21-29 are added.

This listing of claims will replace all prior versions and listings of claims:

1-12. (Canceled)

13. (Currently Amended) A method for treating or preventing obesity which comprises administering to humans ~~or animals~~ a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition.

14. (Previously Presented) A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition is administered orally or parenterally.

15. (Previously Presented) A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition is in a form selected from the group consisting of compositions for injection, compositions for dripping, suppositories, nasal agents, sublingual agents and percutaneous absorption agents.

16. (Previously Presented) A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition further comprises pharmaceutically acceptable carriers, excipients, stabilizers, coloring matters, or surfactants.

17. (Previously Presented) A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition is a composition formulated for injection comprising a pharmacologically effective amount of stanniocalcin and at least one pharmaceutically acceptable excipient and/or activator.

18. (Previously Presented) A method for treating or preventing obesity according to claim 17 wherein said excipient and/or activator comprise amino acids, human serum albumin, sugars, and/or cellulose derivatives.

19. (Previously Presented) A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition is administered at a daily dose of 10 μ g to 10 mg/kg body weight.

20. (Previously Presented) A method for treating or preventing obesity according to claim 13 wherein said pharmaceutical composition is administered intravenously.

21. (NEW) A method for treating or preventing obesity which comprises administering to animals a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition.

22. (NEW) A method for inhibiting adipocyte activity which comprises administering to humans a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition.

23. (NEW) A method for inhibiting adipocyte activity according to Claim 22, wherein adipocyte differentiation is inhibited.

24. (NEW) A method for inhibiting adipocyte activity according to Claim 22, wherein adipocyte maturation is inhibited.

25. (NEW) A method for inhibiting adipocyte activity which comprises administering to animals a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition.

26. (NEW) A method for inhibiting adipocyte activity according to Claim 25, wherein adipocyte differentiation is inhibited.

27. (NEW) A method for inhibiting adipocyte activity according to Claim 25, wherein adipocyte maturation is inhibited.

28. (NEW) A method for inhibiting adipogenesis in adipocytes comprising administering a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition.

29. (NEW) A method for treating obesity which comprises administering to humans a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition.